Literature DB >> 24361860

A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma.

Chantelle Bennetto-Hood1, Glenn Tabolt2, Paul Savina3, Edward P Acosta4.   

Abstract

A sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) assay was developed and validated to facilitate the assessment of clinical pharmacokinetics of dolutegravir (DTG) in plasma samples. This work describes an assay system requiring only a 20μL aliquot of human plasma that is subjected to a simple acetonitrile protein precipitation containing a stably labeled isotope of DTG used as an internal standard. Chromatography was performed on an XBridge C18, 2.1mm×50mm, reversed phase analytical column, using a 60:40 acetonitrile/water mobile phase containing 0.1% formic acid. Detection of the analyte and internal standard was achieved by ESI positive ionization tandem mass spectrometry. The precursor/product transitions (m/z) monitored were 420.1/136.0 and 428.1/283.1 for DTG and DTG-IS, respectively. The dynamic range of this assay extends from 5 to 10,000ng/mL, with a mean coefficient of determination (r, mean±SD) of 0.9996±0.0003. The mean precision values for calibration standards ranged from 0.7 to 4.1%, while accuracy values were 98.3 to 102.0%. Validation results demonstrated high accuracy (≤6.5% deviation) and high precision (≤9.1% CV) for the quality control samples. This assay system provides an accurate, precise, and sensitive method for DTG quantitation and was successfully applied to clinical research samples as part of a phase I/II pediatric clinical trial.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ARVs; AUC; AcN; CV; DMSO; DTG; Dolutegravir; EDTA; EFV; EVG; HIV; Human; INSTI; IPA; IS; Integrase inhibitor; LC–MS/MS; LLOQ; MRM; Mass spectrometry; MeOH; NRTI; PK; QC; RAL; UDP-glucuronosyl transferase 1A1; UGT1A1; ULQ; acetonitrile; antiretrovirals; area under the concentration–time curve; coefficient of variation; dimethyl sulfoxide; dolutegravir; efavirenz; elvitegravir; ethylenediamine tetraacetic acid; human immunodeficiency virus; integrase strand transfer inhibitor; internal standard; isopropanol; liquid chromatography tandem mass spectrometry; lower limit of quantitation; methanol; multi reaction monitoring; nucleoside reverse transcriptase inhibitor; pharmacokinetic; quality control; raltegravir; upper limit of quantitation

Mesh:

Substances:

Year:  2013        PMID: 24361860      PMCID: PMC4229012          DOI: 10.1016/j.jchromb.2013.11.054

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  13 in total

1.  Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers.

Authors:  Parul Patel; Ivy Song; Julie Borland; Apurva Patel; Yu Lou; Shuguang Chen; Toshihiro Wajima; Amanda Peppercorn; Sherene S Min; Stephen C Piscitelli
Journal:  J Antimicrob Chemother       Date:  2011-04-14       Impact factor: 5.790

2.  Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.

Authors:  Jan van Lunzen; Franco Maggiolo; José R Arribas; Aza Rakhmanova; Patrick Yeni; Benjamin Young; Jürgen K Rockstroh; Steve Almond; Ivy Song; Cindy Brothers; Sherene Min
Journal:  Lancet Infect Dis       Date:  2011-10-20       Impact factor: 25.071

Review 3.  Integrase inhibitors to treat HIV/AIDS.

Authors:  Yves Pommier; Allison A Johnson; Christophe Marchand
Journal:  Nat Rev Drug Discov       Date:  2005-03       Impact factor: 84.694

4.  Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.

Authors:  Ivy Song; Julie Borland; Shuguang Chen; Yu Lou; Amanda Peppercorn; Toshihiro Wajima; Sherene Min; Stephen C Piscitelli
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

5.  Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

Authors:  Pedro Cahn; Anton L Pozniak; Horacio Mingrone; Andrey Shuldyakov; Carlos Brites; Jaime F Andrade-Villanueva; Gary Richmond; Carlos Beltran Buendia; Jan Fourie; Moti Ramgopal; Debbie Hagins; Franco Felizarta; Jose Madruga; Tania Reuter; Tamara Newman; Catherine B Small; John Lombaard; Beatriz Grinsztejn; David Dorey; Mark Underwood; Sandy Griffith; Sherene Min
Journal:  Lancet       Date:  2013-07-03       Impact factor: 79.321

6.  The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults.

Authors:  Mark R Underwood; Brian A Johns; Akihiko Sato; Jeffrey N Martin; Steven G Deeks; Tamio Fujiwara
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

7.  Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir.

Authors:  Ivy Song; Julie Borland; Sherene Min; Yu Lou; Shuguang Chen; Parul Patel; Toshihiro Wajima; Stephen C Piscitelli
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

8.  Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.

Authors:  Sherene Min; Ivy Song; Julie Borland; Shuguang Chen; Yu Lou; Tamio Fujiwara; Stephen C Piscitelli
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

9.  In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.

Authors:  Melinda J Reese; Paul M Savina; Grant T Generaux; Helen Tracey; Joan E Humphreys; Eri Kanaoka; Lindsey O Webster; Kelly A Harmon; James D Clarke; Joseph W Polli
Journal:  Drug Metab Dispos       Date:  2012-11-06       Impact factor: 3.922

10.  Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.

Authors:  Joseph J Eron; Bonaventura Clotet; Jacques Durant; Christine Katlama; Princy Kumar; Adriano Lazzarin; Isabelle Poizot-Martin; Gary Richmond; Vincent Soriano; Mounir Ait-Khaled; Tamio Fujiwara; Jenny Huang; Sherene Min; Cindy Vavro; Jane Yeo
Journal:  J Infect Dis       Date:  2012-12-07       Impact factor: 5.226

View more
  19 in total

1.  Reverse-polynomial dilution calibration methodology extends lower limit of quantification and reduces relative residual error in targeted peptide measurements in blood plasma.

Authors:  Yunki Y Yau; Xizi Duo; Rupert W L Leong; Valerie C Wasinger
Journal:  Mol Cell Proteomics       Date:  2014-12-09       Impact factor: 5.911

2.  Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study.

Authors:  Pavan Kumar Prathipati; Subhra Mandal; Christopher J Destache
Journal:  J Pharm Biomed Anal       Date:  2016-07-26       Impact factor: 3.935

3.  Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.

Authors:  Nikki Mulligan; Brookie M Best; Jiajia Wang; Edmund V Capparelli; Alice Stek; Emily Barr; Shelley L Buschur; Edward P Acosta; Elizabeth Smith; Nahida Chakhtoura; Sandra Burchett; Mark Mirochnick
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

4.  Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.

Authors:  Babafemi O Taiwo; Vincent C Marconi; Baiba Berzins; Carlee B Moser; Amesika N Nyaku; Carl J Fichtenbaum; Constance A Benson; Timothy Wilkin; Susan L Koletar; Jonathan Colasanti; Edward P Acosta; Jonathan Z Li; Paul E Sax
Journal:  Clin Infect Dis       Date:  2018-05-17       Impact factor: 9.079

5.  ABCG2 Deficiency Does Not Alter Dolutegravir Metabolism and Pharmacokinetics.

Authors:  Junjie Zhu; Xin Tian; Amina I Shehu; Deborah K McMahon; Xiaochao Ma
Journal:  J Pharmacol Exp Ther       Date:  2020-04-17       Impact factor: 4.030

6.  HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy.

Authors:  Cecile D Lahiri; Nakita L Brown; Kevin J Ryan; Edward P Acosta; Anandi N Sheth; Cyra C Mehta; Jessica Ingersoll; Ighovwerha Ofotokun
Journal:  AIDS       Date:  2018-09-24       Impact factor: 4.177

7.  Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093.

Authors:  Rolando M Viani; Carmelita Alvero; Terry Fenton; Edward P Acosta; Rohan Hazra; Ellen Townley; Debra Steimers; Sherene Min; Andrew Wiznia
Journal:  Pediatr Infect Dis J       Date:  2015-11       Impact factor: 2.129

8.  HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus.

Authors:  Elias K Halvas; Kevin W Joseph; Leah D Brandt; Shuang Guo; Michele D Sobolewski; Jana L Jacobs; Camille Tumiotto; John K Bui; Joshua C Cyktor; Brandon F Keele; Gene D Morse; Michael J Bale; Wei Shao; Mary F Kearney; John M Coffin; Jason W Rausch; Xiaolin Wu; Stephen H Hughes; John W Mellors
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

9.  Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients.

Authors:  Jianping Zhang; Siobhán Hayes; Brian M Sadler; Ilisse Minto; Julie Brandt; Steve Piscitelli; Sherene Min; Ivy H Song
Journal:  Br J Clin Pharmacol       Date:  2015-07-14       Impact factor: 4.335

10.  Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol.

Authors:  Ivy H Song; Julie Borland; Shuguang Chen; Toshihiro Wajima; Amanda F Peppercorn; Stephen C Piscitelli
Journal:  Ann Pharmacother       Date:  2015-04-10       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.